Here are the 10-K annual reports from Gilead Sciences Inc (GILD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GILD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GILD filings page.
Gilead Sciences is a large biopharmaceutical company focused on HIV, liver disease, COVID-19 and oncology, with a global presence in more than 35 countries. Its medicines include HIV regimens like Biktarvy and Descovy, liver treatments such as Epclusa and Vemlidy, COVID-19 therapy Veklury, and cell therapies Yescarta and Tecartus.
The company highlights a broad late‑stage pipeline in virology and oncology, including lenacapavir for HIV prevention, bulevirtide for hepatitis delta, and multiple CAR T and antibody‑drug conjugate programs. It emphasizes extensive patent protection, with key products such as Biktarvy and Veklury covered into the 2030s, and notes growing pricing and reimbursement pressures from U.S. policy changes like the Inflation Reduction Act, Medicaid and 340B rules, and international cost controls.
Gilead also describes significant manufacturing infrastructure in the U.S., Europe and Canada, reliance on contract manufacturers, and a workforce of about 17,000 employees. It stresses human capital, ESG priorities and detailed risk factors spanning competition, product demand volatility, regulatory change, climate rules and complex U.S. drug‑pricing reforms.